🟢 LLY is trading 2.2% up today after a $1.9B Abbisko deal and China obesity drug optimism

LLY is trading 2.2% up at $1141.61 following news of a potential $1.9 billion research collaboration with Abbisko Therapeutics.

• The partnership is complemented by renewed optimism regarding a potential late-2026 China launch for Lilly’s oral obesity drug, which is strengthening sentiment around the company's pipeline.
• The price action is company-specific rather than macro-driven, with the stock attracting targeted biotech interest and active trading volume despite mixed broader markets.